Kenvue Inc. (NYSE:KVUE) Given Consensus Rating of “Hold” by Brokerages

Shares of Kenvue Inc. (NYSE:KVUE) have been given a consensus recommendation of “Hold” by the fourteen analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $23.00.

KVUE has been the subject of several research analyst reports. Canaccord Genuity Group lowered their target price on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Bank of America increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Barclays lowered their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Finally, UBS Group cut their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th.

Kenvue Stock Up 0.2 %

KVUE stock opened at $20.96 on Thursday. The firm has a market cap of $40.19 billion, a PE ratio of 39.55, a PEG ratio of 2.16 and a beta of 1.45. Kenvue has a one year low of $17.67 and a one year high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm’s 50 day moving average price is $21.41 and its 200-day moving average price is $22.03.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities research analysts anticipate that Kenvue will post 1.05 EPS for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.91%. Kenvue’s payout ratio is 154.72%.

Institutional Investors Weigh In On Kenvue

Hedge funds have recently bought and sold shares of the stock. Huber Capital Management LLC grew its position in shares of Kenvue by 15.6% during the fourth quarter. Huber Capital Management LLC now owns 169,300 shares of the company’s stock worth $3,615,000 after buying an additional 22,900 shares in the last quarter. Allen Wealth Management LLC lifted its stake in Kenvue by 7.8% in the fourth quarter. Allen Wealth Management LLC now owns 82,559 shares of the company’s stock worth $1,763,000 after acquiring an additional 6,001 shares during the last quarter. Westpac Banking Corp grew its holdings in Kenvue by 68.5% during the 4th quarter. Westpac Banking Corp now owns 325,615 shares of the company’s stock worth $6,952,000 after acquiring an additional 132,327 shares in the last quarter. Bryce Point Capital LLC purchased a new stake in shares of Kenvue in the 4th quarter valued at approximately $469,000. Finally, Huntington National Bank raised its holdings in shares of Kenvue by 44.4% in the 4th quarter. Huntington National Bank now owns 6,007 shares of the company’s stock valued at $128,000 after purchasing an additional 1,846 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.